Fig. 1

The expression, methylation and gene mutation of MYO5A in HNSC. A The transcriptional level of MYO5A in normal tissues and HNSCC (head and neck squamous cell carcinoma) based on TCGA database (TCGA RNAseq data). B The differential expression analysis of MYO5A between male and female HNSCC patients was conducted using UALCAN based on TCGA database. C The differential expression analysis of MYO5A in HNSCC patients with different race (Caucasian, African-american and Asian) was conducted using UALCAN based on TCGA database. D Spearman correlation analysis was made between DNA methylation and gene expression of MYO5A in HNSCC patients according to TCGA database. E DNA methylation level of MYO5A in normal tissues and HNSCC based on TCGA database. F The copy number alterations (Deep deletion, Shallow deletion, Diploid, Gain and Amplification) and expression levels of MYO5A in HNSCC patients using cBioportal. G-H The overall mutational spectrum of MYO5A in pan-cancer were performed by cBioportal based on TCGA database. I 3D protein structure prediction and their expected prediction error of MYO5A in human, mouse and rat were performed by AlphaFold Protein Structure Database. The colour at position (x, y) indicates AlphaFold’s expected position error at residue x, when the predicted and true structures are aligned on residue y. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Some regions below 50 pLDDT may be unstructured in isolation. Data are presented as mean ± SD. *, P < 0.05; **, P < 0.01, ***, P < 0.001